Home
About Symray
Company Profile Milestones Management Team
Technology Platforms
Antibody Discovery Platform Antibody Characterization Platform Drug Validation Platform
Pipeline
Lead & Candidate Antibody Drugs Hit Antibodies
External Collaboration
Collaboration Models Partners
News
Join Us
Corporate Culture Careers Contact Us
中文
Home
About Symray
Company Profile Milestones Management Team
Technology Platforms
Pipeline
External Collaboration
Collaboration Models Partners
News
Join Us
Corporate Culture Careers Contact Us
Pipeline
Home Pipeline Hit Antibodies
Lead & Candidate Antibody Drugs Hit Antibodies
SY0023
PSMA
Solid tumors
SY0538
Mesothelin
Solid tumors
SY0625
FRA
Solid tumors
SY0828
IL-5Rα/CD125
Solid tumors
SY0831
Nectin-4
Solid tumors
SY0883
B7-H3/CD276
Solid tumors
SY1211
ROR1
Solid tumors
Hematologic malignancies
SY1274
DLL3
Solid tumors
SY1330
Not specified
Solid tumors
SY1556
LGR4
Solid tumors
SY1558
LILRB4/CD85k
Solid tumors
Hematologic malignancies
SY1600
LILRB1/CD85J
Solid tumors
Hematologic malignancies
SY1601
LILRB2/CD85D
Solid tumors
SY1604
FGFR4/CD334
Solid tumors
SY1606
FGFR2IIIb/CD332
Solid tumors
SY1700
TF/CD142
Solid tumors
1
About Symray
Company Profile Milestones Management Team
Technology Platforms
Antibody Discovery Platform Antibody Characterization Platform Drug Validation Platform
Pipeline
Lead & Candidate Antibody Drugs Hit Antibodies
External Collaboration
Collaboration Models Partners
News
News
Join Us
Corporate Culture Careers Contact Us
WeChat Official Account
© 2023 Shanghai Symray Biopharma Co., Ltd. All rights reserved. Shanghai Public Security Filing No. Xx0xxxxxx0xxX | Shanghai ICP Filing No. Xxx0xxx0xxx0xx00xX